GLP-3 (RT)

Retatrutide (research code LY3437943, informally 'GLP-3') is a lab-made peptide engineered to activate three metabolic receptors at once — GLP-1, GIP, and glucagon. It is an investigational compound still in clinical trials, and it is supplied here as an analytical-grade reference material for laboratory research use only.

Because a single molecule switches on three different hormone receptors instead of one or two. GLP-1 and GIP are gut 'incretin' signals, while glucagon adds a distinct action on energy expenditure and the liver's handling of fat. Combining all three is what makes it unusual to study.

Yes, more than most research peptides. Its published evidence comes largely from Phase 2 human trials in obesity, type 2 diabetes, and metabolic fatty-liver disease, with a larger Phase 3 program (TRIUMPH) still ongoing. It is important to note that it remains investigational and is not an approved medicine.

Semaglutide acts on one receptor (GLP-1) and tirzepatide on two (GIP and GLP-1); retatrutide adds a third, the glucagon receptor. In trials that third signal has been associated with larger body-weight change and reductions in liver fat, though it also makes the compound more complex to study.

No. Retatrutide here is strictly an analytical-grade reference material for laboratory research use only. Although its clinical trials measured body-weight change, this material is not sold for personal use, is not a medicine, and nothing here is health or dosing advice.